AndreaBozzo/ceres-open-data-index huggingface dataset:
Hospital Inpatient Discharges (SPARCS De-Identified): 2023

The Statewide Planning and Research Cooperative System (SPARCS) Inpatient De-identified File contains discharge level detail on patient characteristics, diagnoses, treatments, services, and charges.

This data file contains basic record level detail for the discharge. The de-identified data file does not contain data that is protected health information (PHI) under HIPAA. The health information is not individually identifiable; all data elements considered identifiable have been redacted. For example, the direct identifiers regarding a date have the day and month portion of the date removed.

For more information visit: https://www.health.ny.gov/statistics/sparcs/
2014 CMHS Uniform Reporting System (URS) Table for California

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for California. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 529144: 1-Dodecanamine, bis-TMS

Chemical compound data from PubChem database. IUPAC Name: N,N-bis(trimethylsilyl)dodecan-1-amine. Molecular Formula: C18H43NSi2. Molecular Weight: 329.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526471: Methyl perfluoroheptanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptanoate. Molecular Formula: C8H3F13O2. Molecular Weight: 378.09. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399511-T1: [Translated] BRANCH LONGITUDINALLY FLEXIBLE STENT

There is disclosed a method of stent placement which comprises first guiding a guidewire through the vasculature. Second, a balloon catheter which contains two guidewire lumens is strung along the guidewire into position at the bifurcation. The distal opening of the second guidewire lumen abuts the proximal end of the bifurcation. Thereafter, a second guidewire is strung through the first balloon catheter and out the distal opening of the second guidewire lumen. Thus, resident in the second bifurcation leg is the second guidewire. Then, a second standard stent delivery balloon catheter is guided along the second guidewire to a position within the bifurcation. Typically, expansion of both stents can be done one right after the other after proper placement of the first and second balloons. <IMAGE>
Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve?

Introduction
          Dehydroepiandrosterone (DHEA) and its sulphate (DHEAS) are pleiotropic adrenal hormones with immunostimulating and antiglucocorticoid effects. The present study was conducted to evaluate the time course of DHEAS levels in critically ill patients and to study their association with the hypothalamic–pituitary–adrenal axis.
        
        
          Materials and method
          This was a prospective observational clinical and laboratory study, including 30 patients with septic shock, eight patients with multiple trauma, and 40 age- and sex-matched control patients. We took serial measurements of blood concentrations of DHEAS, cortisol, tumour necrosis factor-α and IL-6, and of adrenocorticotrophic hormone immunoreactivity over 14 days or until discharge/death.
        
        
          Results
          On admission, DHEAS was extremely low in septic shock (1.2 ± 0.8 mol/l) in comparison with multiple trauma patients (2.4 ± 0.5 μmol/l; P < 0.05) and control patients (4.2 ± 1.8; P < 0.01). DHEAS had a significant (P < 0.01) negative correlation with age, IL-6 and Acute Physiology and Chronic Health Evaluation II scores in both patient groups. Only during the acute phase did DHEAS negatively correlate with dopamine. Nonsurvivors of septic shock (n = 11) had lower DHEAS levels (0.4 ± 0.3 μmol/l) than did survivors (1.7 ± 1.1 μmol/l; P < 0.01). The time course of DHEAS exhibited a persistent depletion during follow up, whereas cortisol levels were increased at all time points.
        
        
          Conclusion
          We identified extremely low DHEAS levels in septic shock and, to a lesser degree, in multiple trauma patients as compared with those of age- and sex-matched control patients. There appeared to be a dissociation between DHEAS (decreased) and cortisol (increased) levels, which changed only slightly over time. Nonsurvivors of sepsis and patients with relative adrenal insufficiency had the lowest DHEAS values, suggesting that DHEAS might be a prognostic marker and a sign of exhausted adrenal reserve in critical illness.
Influence of twenty-five per cent human serum albumin on total and
		  ionized calcium concentrations

Background:
          A inverse correlation has been found between changes in ionized
				calcium concentrations and the addition of albumin in vitro, which may
				explain adverse cardiovascular effects attributed to exogenous albumin in
				vivo. The purpose of this investigation was to determine the interaction
				(if any) between exogenous 25% albumin administration (100 ml given over
				< 30 min) and calcium concentrations in patients, all but one of whom were in
				an intensive care unit.
        
        
          Results:
          There were no significant differences in the ionized calcium
				concentrations obtained before, at the end and 6 h after the administration of
				albumin (1.09 ± 0.23, 1.06 ± 0.22, 1.06 ± 0.21 mmol/l,
				respectively). Similarly, there were no significant differences in the total
				calcium concentrations between these same time periods (2.03 ± 0.18,
				2.05 ± 0.20, 2.08 ± 0.23 mmol/l, respectively).
        
        
          Conclusions:
          In patients receiving infusions of 25% albumin, it appears that
				circulating calcium concentrations are well regulated by homeostatic
				mechanisms. Albumin infusions had no effect on calcium concentrations, although
				it is possible that temporary changes of questionable clinical importance may
				have occurred between measurement periods.
A comparison of volume control and pressure-regulated volume control ventilation in acute respiratory failure

Background:
          The aim of this study was to test the hypothesis that a new mode of ventilation (pressure-regulated volume control; PRVC) is associated with improvements in respiratory mechanics and outcome when compared with conventional volume control (VC) ventilation in patients with acute respiratory failure. We conducted a randomised, prospective, open, cross over trial on 44 patients with acute respiratory failure in the general intensive care unit of a university hospital. After a stabilization period of 8 h, a cross over trial of 2 × 2 h was conducted. Apart from the PRVC/VC mode, ventilator settings were comparable. The following parameters were recorded for each patient: days on ventilator, failure in the assigned mode of ventilation (peak inspiratory pressure  > 50 cmH2O) and survival.
        
        
          Results:
          In the crossover trial, peak inspiratory pressure was significantly lower using PRVC than with VC (20 cmH2O vs 24 cmH2O, P < 0.0001). No other statistically significant differences were found.
        
        
          Conclusions:
          Peak inspiratory pressure was significantly lower during PRVC ventilation than during VC ventilation, and thus PRVC may be superior to VC in certain patients. However, in this small group of patients, we could not demonstrate that PRVC improved outcome.
Compound 526625: 2-[2-(2-Diethylamino-ethoxy)-eth oxy]-ethanol

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-(diethylamino)ethoxy]ethoxy]ethanol. Molecular Formula: C10H23NO3. Molecular Weight: 205.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527284: 3,7-Dimethyloct-6-enyl 4-methylvalerate

Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethyloct-6-enyl 4-methylpentanoate. Molecular Formula: C16H30O2. Molecular Weight: 254.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529800: Valine, trifluoroacetyl-isopropyl ester

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 3-methyl-2-[(2,2,2-trifluoroacetyl)amino]butanoate. Molecular Formula: C10H16F3NO3. Molecular Weight: 255.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Carvedilol phosphate

Carvedilol Phosphate is a generic prescription medication available as extended-release oral capsules in strengths of 10mg, 20mg, 40mg, and 80mg. It acts as an alpha and beta adrenergic blocker, commonly used to treat high blood pressure and heart failure by relaxing blood vessels and reducing heart workload. Manufactured by Amneal Pharmaceuticals. This information was generated using AI and is provided for informational and research purposes only.
Compound 529430: 2(1H)-Naphthalenone, 7-methoxy

Chemical compound data from PubChem database. IUPAC Name: 7-methoxy-1H-naphthalen-2-one. Molecular Formula: C11H10O2. Molecular Weight: 174.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2008 CMHS Uniform Reporting System Output Tables

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2008. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.
Seismic compliance data by county for general acute care hospitals

Data for seismic compliance in general acute care hospitals is grouped by counties. All general acute care hospital buildings are assigned a Structural Performance Category (SPC) which measures the probable seismic performance of building structural systems. Building structural systems include beams, columns, shear walls, slabs, and foundations. SPC ratings range from 1 to 5 with SPC 1 assigned to buildings that may be at risk of collapse during a strong earthquake and SPC 5 assigned to buildings reasonably capable of providing services to the public following a strong earthquake. State law requires all SPC 1 buildings to be removed from providing general acute care services by January 1, 2020, unless an approved extension has been granted, and all SPC 2 buildings to be removed from providing general acute care services by January 1, 2030. A hospital facility meets the January 1, 2030 requirements if all the general acute care buildings on campus are SPC and NPC compliant. 2030 compliant SPC ratings are either SPC 3, 4, 4D, or 5. 2030 compliant NPC ratings is NPC 5. Data is provided for both hospital facilities and hospital buildings. Data is updated approximately every two weeks.
Medi-Cal Managed Care Capitation Rates - Senior Care Action Network (SCAN)

Medi-Cal Managed Care Capitation Rates for Capitated Rates for Senior Care Action Network (SCAN) – by Calendar Year. Senior Care Action Network (SCAN) Health Plan is a Medicare Advantage Special Needs Plan that contracts with the Department of Health Care Services for dual eligible Medicare/Medi-Cal population subset residing in Los Angeles, San Bernardino, and Riverside counties.
Compound 528376: Pentane, 2,4-dimethyl-3-methylene-

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-3-methylidenepentane. Molecular Formula: C8H16. Molecular Weight: 112.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2015 CMHS Uniform Reporting System (URS) Table for Michigan

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Michigan. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527357: 18,22,26,30-Tetramethyl-tritriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 19,23,27,31-tetramethyltetratriacontanenitrile. Molecular Formula: C38H75N. Molecular Weight: 546.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528942: 4-(Octylphenyl-3,6-dimethyl-1-cyclohexenyl ether

Chemical compound data from PubChem database. IUPAC Name: 1-(3,6-dimethylcyclohexen-1-yl)oxy-4-octylbenzene. Molecular Formula: C22H34O. Molecular Weight: 314.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table 1C. Arboviral diseases, St. Louis encephalitis virus disease to West Nile virus disease

NNDSS - Table 1C. Arboviral diseases, St. Louis encephalitis virus disease to West Nile   virus disease - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Diclofenac does not interact with codeine metabolism in vivo: A study in healthy volunteers

Background
          Previously, we have demonstrated a marked inhibition of codeine glucuronidation by diclofenac in human liver tissue homogenate. We therefore aimed to investigate whether diclofenac inhibits glucuronidation of codeine also in vivo in healthy volunteers.
        
        
          Methods
          In a randomised, placebo-controlled, double-blind, cross-over study, 12 healthy volunteers received a singe of 100 mg codeine phosphate plus 50 mg diclofenac sodium or codeine phosphate plus placebo. Over a 36 hour period serum concentrations of codeine and its metabolites as well as urinary excretion were analysed using LC-mass spectrometry. Side effects were recorded and analgesic efficacy was determined using the cold pressor test (0–6 h).
        
        
          Results
          A single dose of diclofenac did not alter the formation of codeine-6-glucuronide in healthy volunteers. Metabolic clearance of codeine to morphine was not affected by diclofenac. In terms of side effects, both treatments were well tolerated. Diclofenac did not significantly influence the analgesic effects of codeine in the cold pressor test.
        
        
          Conclusions
          In contrast to recent in vitro data, a single oral dose of diclofenac did not alter the glucuronidation of codeine in healthy volunteers.
Patent AT-E400149-T1: [Translated] RECONFIGURING DIVERSITY PATHS DURING CN-RNC INTERFACE TRANSFER

In a mobile communications network that employs diversity combining/splitting, CN-RNC interface streamlining can be accomplished more efficiently by reconfiguring the network diversity legs, which are combined into a single data stream by the serving radio network controller, wherein the serving radio network controller is directly connected to the core network via the CN-RNC interface. Reconfiguration of the network diversity legs is accomplished by releasing the transport level connections which support the network diversity legs prior to CN-RNC interface streamlining, and establishing new transport level connections to support the reconfigured, network diversity legs subsequent to CN-RNC interface streamlining. To establish new transport level connections, the serving radio network controller dispatches binding information to each of the destination nodes associated with the network diversity legs. The destination nodes then utilize the binding information to bind network resources to the transport level connections which support the reconfigured network diversity legs between the destination nodes and the serving radio network controller.
Compound 526955: 2-Nitrophenyl-3-nitrophenylacetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(2-nitrophenyl)-2-(3-nitrophenyl)acetate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528673: Trimethylsilyl 3-(3-methoxy-4-[(trimethylsilyl)oxy]phenyl)-3-[(trimethylsilyl)oxy]propanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(3-methoxy-4-trimethylsilyloxyphenyl)-3-trimethylsilyloxypropanoate. Molecular Formula: C19H36O5Si3. Molecular Weight: 428.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525251: N''-(4-methyl-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 1,1,3,3-tetramethyl-2-(4-methylphenyl)guanidine. Molecular Formula: C12H19N3. Molecular Weight: 205.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525826: N,N-Dimethyl-N'-(3-methoxyphenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-methoxyphenyl)-N,N-dimethylpropanimidamide. Molecular Formula: C12H18N2O. Molecular Weight: 206.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527537: Perfluoro-3,4-dimethyl-4-ethylhex-2-ene

Chemical compound data from PubChem database. IUPAC Name: 1,1,1,2,5,5,6,6,6-nonafluoro-4-(1,1,2,2,2-pentafluoroethyl)-3,4-bis(trifluoromethyl)hex-2-ene. Molecular Formula: C10F20. Molecular Weight: 500.07. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women

Background
          Little empirical research has examined the multiple consequences of osteoporosis on quality of life.
        
        
          Methods
          Health related quality of life (HRQL) was examined in relationship to incident fractures in 2009 postmenopausal women 50 years and older who were seen in consultation at our tertiary care, university teaching hospital-affiliated office and who were registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO) patients. Patients were divided into three study groups according to incident fracture status: vertebral fractures, non-vertebral fractures and no fractures. Baseline assessments of anthropometric data, medical history, therapeutic drug use, and prevalent fracture status were obtained from all participants. The disease-targeted mini-Osteoporosis Quality of Life Questionnaire (mini-OQLQ) was used to measure HRQL.
        
        
          Results
          Multiple regression analyses revealed that subjects who had experienced an incident vertebral fracture had lower HRQL difference scores as compared with non-fractured participants in total score (-0.86; 95% confidence intervals (CI): -1.30, -0.43) and the symptoms (-0.76; 95% CI: -1.23, -0.30), physical functioning (-1.12; 95% CI: -1.57, -0.67), emotional functioning (-1.06; 95% CI: -1.44, -0.68), activities of daily living (-1.47; 95% CI: -1.97, -0.96), and leisure (-0.92; 95% CI: -1.37, -0.47) domains of the mini-OQLQ. Patients who experienced an incident non-vertebral fracture had lower HRQL difference scores as compared with non-fractured participants in total score (-0.47; 95% CI: -0.70, -0.25), and the symptoms (-0.25; 95% CI: -0.49, -0.01), physical functioning (-0.39; 95% CI: -0.65, -0.14), emotional functioning (-0.97; 95% CI: -1.20, -0.75) and the activities of daily living (-0.47; 95% CI: -0.73, -0.21) domains.
        
        
          Conclusion
          Quality of life decreased in patients who sustained incident vertebral and non-vertebral fractures.